March 16th 2025
Carl Schmid, executive director, HIV + Hepatitis Policy Institute, explains how a Supreme Court case could have far reaching implications for greater health screenings and preventative services beyond HIV and hepatitis.
Implants of Tenofovir Alafenamide Could Provide Protection for 6 Months, Study Says
April 12th 2019Subcutaneous implants are 1 promising strategy to address suboptimal adherence to pre-exposure prophylaxis (PrEP) for HIV, and a recent in silico simulation examined pharmacokinetic profiles and safety of tenofovir alafenamide implants.
Read More